13F Holdings
中文EN

CRBP Corbus Pharmaceuticals Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1595097 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-72.3%
TTM EPS YoY-10.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-131.5%
ROA-100.1%
ROIC (approx.)-160.1%
Asset turnover—

Leverage & solvency

Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-20.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$0$881,705
R&D expense$70.09M$32.22M$31.17M$16.14M$36.45M
SG&A expense$15.21M$16.50M$13.91M$18.70M$20.43M
Operating income-$85.31M-$48.72M-$45.08M-$39.84M-$55.99M
Interest expense$0$1.87M$3.86M$3.10M$2.71M
Income tax$0$0———
Net income-$78.54M-$40.21M-$44.60M-$42.35M-$45.64M
EBITDA-$85.08M-$48.13M-$44.44M-$39.07M-$54.99M
EPS (basic)-5.90-3.68-10.31-10.15-11.15
EPS (diluted)-5.90-3.68-10.31-10.15-11.15
Weighted avg. shares (diluted)13.32M10.92M4.33M4.17M4.09M
Banking
Net interest income——-$2.92M-$2.13M-$1.83M
Balance sheet
Cash & equivalents$28.49M$17.20M$13.72M$17.00M$25.01M
Short-term investments$134.78M$131.86M$7.18M$42.19M$72.64M
Current assets$166.95M$152.98M$23.55M$60.18M$100.20M
PP&E, net$159,000$385,000$973,000$1.61M$2.39M
Total assets$168.19M$155.88M$28.27M$66.31M$107.73M
Current liabilities$20.69M$11.82M$31.89M$12.64M$17.01M
Short-term debt——$15.91M$2.80M$3.09M
Long-term debt——$0$15.98M$15.64M
Total debt——$15.91M$18.78M$18.73M
Total liabilities$20.69M$13.45M$35.18M$33.32M$38.62M
Shareholders' equity$147.50M$142.43M-$6.91M$32.99M$69.11M
Net debt——$2.18M$1.78M-$6.28M
Shares outstanding17.61M12.18M4.42M4.17M4.17M
Cash flow statement
Operating cash flow-$64.49M-$41.79M-$36.10M-$37.54M-$48.18M
Capital expenditure$7,000$0$0$13,449$54,172
Free cash flow-$64.50M-$41.79M-$36.10M-$37.56M-$48.24M
Investing cash flow-$1.64M-$121.31M$35.64M$30.07M-$73.42M
Financing cash flow$77.43M$166.58M-$2.82M-$533,615$60.82M
Depreciation & amortization$233,000$588,000$641,000$762,995$999,817
Stock-based compensation$6.29M$6.14M$3.47M$5.72M$9.48M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.